Last updated: April 23, 2026
Who supplies memantine hydrochloride at the API (active pharmaceutical ingredient) level?
Memantine hydrochloride (API) is manufactured by multiple commercial API producers and supplied through branded and generic drug supply chains. The practical “supplier” universe for a business buyer typically splits into two tiers:
1) API manufacturers (direct drug substance sources)
2) API distributors / relabelers (intermediaries that procure from API makers and sell to formulators)
Because memantine is widely used in finished-dose generics and has longstanding supply, buyers commonly source either from API manufacturers with DMF/CEP support or from distributors that hold audit-ready documentation.
Which suppliers are documented for memantine hydrochloride API (trade and regulatory footprints)?
The supplier list below reflects companies that are publicly documented in regulatory/industry contexts for memantine hydrochloride API supply, either as API manufacturers or through long-standing supply-chain presence (including DMF/CEP-backed manufacture and commercial API offerings).
API manufacturer and supply-chain participants commonly associated with memantine hydrochloride
- Aurobindo Pharma
- Cadila Healthcare (Zydus)
- Cipla
- Hetero Drugs
- Lupin
- Mylan / Viatris
- Teva (through legacy and supply-chain entities)
- Sun Pharma
- Torrent Pharmaceuticals
- Dr. Reddy’s Laboratories
Distributor / relabeler channel (typical buyer routes)
- Pharmaceutical API distributors and trading houses that resell to generic formulators
- Regional wholesale distributors that manage paperwork, batch traceability, and incoming quality controls
(For operational procurement, buyers usually qualify one API source plus one alternate, then lock vendor qualification based on COA, incoming QC results, and regulatory dossier alignment.)
What quality and regulatory signals matter when selecting a memantine hydrochloride supplier?
Memantine hydrochloride is an established, low-complexity small molecule, so supplier differentiation is driven less by chemistry and more by documentation and compliance. For qualification, buyers typically confirm:
- GMP manufacturing site status for the API
- DMF (Drug Master File) or CEP availability for the API
- Batch-to-batch consistency (assay, impurities, residual solvents)
- Endotoxin and microbial limits (where applicable to the route)
- Stability data aligned with finished-dose shelf-life requirements
- Change control history (site changes, process changes, impurity profile changes)
In memantine supply, the strongest commercial signals in procurement are usually:
- DMF/CEP-backed manufacturing by the producer or direct API-trading intermediaries
- Documented audit history and consistent COA release timelines
What do buyer qualification and supplier switching typically look like?
For generic formulation work or bulk-to-finished supply, memantine procurement normally uses a qualification pattern like this:
- Primary API source: selected based on dossier availability (DMF/CEP), supply reliability, and confirmed impurity profile
- Secondary source: qualified as a contingency to avoid launch delays or supply disruption
- Bridging strategy: if a second source changes impurity profile or polymorphic behavior, buyers often run limited in-process controls and confirm finished-dose equivalence using established methods
This is the way most “supplier lists” get turned into operational procurement decisions.
How do finished-dose manufacturers relate to memantine API suppliers?
Many finished-dose manufacturers (generic and branded) do not manufacture API themselves and instead rely on external API sources. In practice:
- The finished-dose label points to finished drug manufacturers
- The API maker is identified by dossier references, DMF holder relationships, or audit documentation
- Generic supply chains often include multiple API sources so that finished manufacturers can maintain continuity
What is the procurement-ready supplier shortlist structure for memantine hydrochloride?
A buyer shortlist that supports fast qualification typically includes:
- 2 to 3 API suppliers with DMF/CEP and stable manufacturing history
- 1 alternate API supply path via a distributor with consistent documentation and rapid COA turnaround
- One regional logistics option to manage lead times and cold-chain needs (generally not cold-chain for memantine API, but handling and warehouse stability still matter)
Key Takeaways
- Memantine hydrochloride API supply is dominated by a multi-supplier ecosystem of established generic API producers and downstream intermediaries.
- Supplier selection hinges on regulatory dossier support (DMF/CEP), GMP site status, impurity profile consistency, and reliable COA and audit readiness.
- Procurement practice is to qualify a primary and at least one alternate source to reduce supply continuity risk.
FAQs
1) Is memantine hydrochloride API typically available from multiple qualified sources?
Yes. Memantine is a long-established generic API with broad commercial availability across multiple major producers.
2) What documentation most often differentiates API suppliers for qualification?
DMF/CEP availability, GMP compliance by the API site, and batch COA alignment on assay and impurities.
3) Do finished-dose manufacturers always produce memantine API in-house?
No. Many finished-dose manufacturers source API externally and qualify based on regulatory documentation and incoming quality performance.
4) What matters most when switching from one memantine API supplier to another?
Impurity profile consistency, residual solvent compliance (if applicable to the process), and finished-dose equivalence confirmation through established analytical methods.
5) What is the practical number of suppliers a buyer should qualify?
Operationally, buyers commonly qualify one primary and one alternate API source, often adding a third as a back-up depending on launch and supply criticality.
References
[1] U.S. Food and Drug Administration (FDA). Orange Book: Approved Drug Products and Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency (EMA). CEP search (European Certificates of Suitability). https://www.ema.europa.eu/en/human-regulatory/research/cep-search
[3] World Health Organization (WHO). International drug regulatory harmonization and GMP resources (context for GMP expectations). https://www.who.int/teams/regulation-prequalification/regulation-and-safety/gmp
[4] PubChem Compound Summary for memantine hydrochloride (chemical substance reference). https://pubchem.ncbi.nlm.nih.gov/
